Effectiveness and safety of seven oral Chinese patent medicines as adjuvant therapy for cancer-related anemia: A systematic review and network meta-analysis of randomized controlled trials
Objective: To evaluate the effectiveness and safety of seven oral Chinese patent medicines (CPMs) as adjuvant therapy for cancer-related anemia (CRA) by network meta-analysis (NMA). Methods: A literature search to obtain randomized controlled trials (RCTs) of seven oral CPMs in the adjuvant treatmen...
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2023-04-01
|
| Series: | Journal of Traditional Chinese Medical Sciences |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2095754823000108 |
| _version_ | 1797701841474027520 |
|---|---|
| author | Jing Xu Kang Wu Xiao Li Chiah Shean Teo Guangda Li Yiming Pan Li Hou |
| author_facet | Jing Xu Kang Wu Xiao Li Chiah Shean Teo Guangda Li Yiming Pan Li Hou |
| author_sort | Jing Xu |
| collection | DOAJ |
| description | Objective: To evaluate the effectiveness and safety of seven oral Chinese patent medicines (CPMs) as adjuvant therapy for cancer-related anemia (CRA) by network meta-analysis (NMA). Methods: A literature search to obtain randomized controlled trials (RCTs) of seven oral CPMs in the adjuvant treatment of CRA was conducted in multiple databases from the inception to April 2022. The RevMan5.3 and R 4.1.1 software were used for NMA. Results: We ultimately included 29 RCTs with 2140 patients. Traditional meta-analysis showed that Fufang E'jiao syrup (FFEJS), Shengxuebao mixture (SXBM), Shengxuening tablets (SXNT), Jianpi Shengxue granules (JPSXG), and Yixuesheng capsule (YXSC) combined with basic Western treatment (BWT) could improve the hemoglobin (HGB) level. JPSXG combined with BWT could improve the red blood cell (RBC). FFEJS combined with BWT improved the Karnofsky performance status (KPS). NMA showed that FFEJS, JPSXG, SXBM, and SXNT plus BWT improved HGB better than Shengxue tablets (SXT) plus BWT, with top three ranking results being JPSXG plus BWT > SXNT plus BWT > FFEJS plus BWT. FFEJS plus BWT, JPSXG plus BWT, SXBM plus BWT, SXNT plus BWT, and SXT plus BWT improved RBC better than BWT, with top three ranking results being SXNT plus BWT > JPSXG plus BWT > FFEJS plus BWT. In terms of the KPS score, compared with SXT plus BWT, FFEJS, JPSXG, SXBM, SXNT, and Yizhong Shengxue capsule (YZSXC) plus BWT had higher KPS, with top three ranking results being SXBM plus BWT > JPSXG plus BWT > FFEJS plus BWT. Conclusions: Our NMA demonstrated that seven oral CPMs used as adjuvant treatment of CRA had a definite clinical effect. JPSXG not only increases the levels of HGB and RBC to enhance the clinical effect but also improves patients' quality of life. More accurate conclusions need to be verified by more high-quality RCTs. |
| first_indexed | 2024-03-12T04:41:33Z |
| format | Article |
| id | doaj.art-fa43c983415c49a987ad0abe12c3e1a9 |
| institution | Directory Open Access Journal |
| issn | 2095-7548 |
| language | English |
| last_indexed | 2024-03-12T04:41:33Z |
| publishDate | 2023-04-01 |
| publisher | Elsevier |
| record_format | Article |
| series | Journal of Traditional Chinese Medical Sciences |
| spelling | doaj.art-fa43c983415c49a987ad0abe12c3e1a92023-09-03T09:41:12ZengElsevierJournal of Traditional Chinese Medical Sciences2095-75482023-04-01102150160Effectiveness and safety of seven oral Chinese patent medicines as adjuvant therapy for cancer-related anemia: A systematic review and network meta-analysis of randomized controlled trialsJing Xu0Kang Wu1Xiao Li2Chiah Shean Teo3Guangda Li4Yiming Pan5Li Hou6First School of Clinical Medicine, Beijing University of Chinese Medicine, Beijing, 100029, China; Department of Oncology and Hematology, Dongzhimen Hospital, Beijing University of Chinese Medicine, Beijing, 100700, ChinaFirst School of Clinical Medicine, Beijing University of Chinese Medicine, Beijing, 100029, ChinaDepartment of Oncology and Hematology, Dongzhimen Hospital, Beijing University of Chinese Medicine, Beijing, 100700, ChinaInstitut Kanser Negara, Ministry of Health Malaysia, Putrajaya, 62250, MalaysiaFirst School of Clinical Medicine, Beijing University of Chinese Medicine, Beijing, 100029, China; Department of Oncology and Hematology, Dongzhimen Hospital, Beijing University of Chinese Medicine, Beijing, 100700, ChinaFirst School of Clinical Medicine, Beijing University of Chinese Medicine, Beijing, 100029, China; Department of Oncology and Hematology, Dongzhimen Hospital, Beijing University of Chinese Medicine, Beijing, 100700, ChinaDepartment of Oncology and Hematology, Dongzhimen Hospital, Beijing University of Chinese Medicine, Beijing, 100700, China; Corresponding author.Objective: To evaluate the effectiveness and safety of seven oral Chinese patent medicines (CPMs) as adjuvant therapy for cancer-related anemia (CRA) by network meta-analysis (NMA). Methods: A literature search to obtain randomized controlled trials (RCTs) of seven oral CPMs in the adjuvant treatment of CRA was conducted in multiple databases from the inception to April 2022. The RevMan5.3 and R 4.1.1 software were used for NMA. Results: We ultimately included 29 RCTs with 2140 patients. Traditional meta-analysis showed that Fufang E'jiao syrup (FFEJS), Shengxuebao mixture (SXBM), Shengxuening tablets (SXNT), Jianpi Shengxue granules (JPSXG), and Yixuesheng capsule (YXSC) combined with basic Western treatment (BWT) could improve the hemoglobin (HGB) level. JPSXG combined with BWT could improve the red blood cell (RBC). FFEJS combined with BWT improved the Karnofsky performance status (KPS). NMA showed that FFEJS, JPSXG, SXBM, and SXNT plus BWT improved HGB better than Shengxue tablets (SXT) plus BWT, with top three ranking results being JPSXG plus BWT > SXNT plus BWT > FFEJS plus BWT. FFEJS plus BWT, JPSXG plus BWT, SXBM plus BWT, SXNT plus BWT, and SXT plus BWT improved RBC better than BWT, with top three ranking results being SXNT plus BWT > JPSXG plus BWT > FFEJS plus BWT. In terms of the KPS score, compared with SXT plus BWT, FFEJS, JPSXG, SXBM, SXNT, and Yizhong Shengxue capsule (YZSXC) plus BWT had higher KPS, with top three ranking results being SXBM plus BWT > JPSXG plus BWT > FFEJS plus BWT. Conclusions: Our NMA demonstrated that seven oral CPMs used as adjuvant treatment of CRA had a definite clinical effect. JPSXG not only increases the levels of HGB and RBC to enhance the clinical effect but also improves patients' quality of life. More accurate conclusions need to be verified by more high-quality RCTs.http://www.sciencedirect.com/science/article/pii/S2095754823000108Cancer-related anemiaChinese patent medicineNetwork meta-analysisEffectivenessSafety |
| spellingShingle | Jing Xu Kang Wu Xiao Li Chiah Shean Teo Guangda Li Yiming Pan Li Hou Effectiveness and safety of seven oral Chinese patent medicines as adjuvant therapy for cancer-related anemia: A systematic review and network meta-analysis of randomized controlled trials Journal of Traditional Chinese Medical Sciences Cancer-related anemia Chinese patent medicine Network meta-analysis Effectiveness Safety |
| title | Effectiveness and safety of seven oral Chinese patent medicines as adjuvant therapy for cancer-related anemia: A systematic review and network meta-analysis of randomized controlled trials |
| title_full | Effectiveness and safety of seven oral Chinese patent medicines as adjuvant therapy for cancer-related anemia: A systematic review and network meta-analysis of randomized controlled trials |
| title_fullStr | Effectiveness and safety of seven oral Chinese patent medicines as adjuvant therapy for cancer-related anemia: A systematic review and network meta-analysis of randomized controlled trials |
| title_full_unstemmed | Effectiveness and safety of seven oral Chinese patent medicines as adjuvant therapy for cancer-related anemia: A systematic review and network meta-analysis of randomized controlled trials |
| title_short | Effectiveness and safety of seven oral Chinese patent medicines as adjuvant therapy for cancer-related anemia: A systematic review and network meta-analysis of randomized controlled trials |
| title_sort | effectiveness and safety of seven oral chinese patent medicines as adjuvant therapy for cancer related anemia a systematic review and network meta analysis of randomized controlled trials |
| topic | Cancer-related anemia Chinese patent medicine Network meta-analysis Effectiveness Safety |
| url | http://www.sciencedirect.com/science/article/pii/S2095754823000108 |
| work_keys_str_mv | AT jingxu effectivenessandsafetyofsevenoralchinesepatentmedicinesasadjuvanttherapyforcancerrelatedanemiaasystematicreviewandnetworkmetaanalysisofrandomizedcontrolledtrials AT kangwu effectivenessandsafetyofsevenoralchinesepatentmedicinesasadjuvanttherapyforcancerrelatedanemiaasystematicreviewandnetworkmetaanalysisofrandomizedcontrolledtrials AT xiaoli effectivenessandsafetyofsevenoralchinesepatentmedicinesasadjuvanttherapyforcancerrelatedanemiaasystematicreviewandnetworkmetaanalysisofrandomizedcontrolledtrials AT chiahsheanteo effectivenessandsafetyofsevenoralchinesepatentmedicinesasadjuvanttherapyforcancerrelatedanemiaasystematicreviewandnetworkmetaanalysisofrandomizedcontrolledtrials AT guangdali effectivenessandsafetyofsevenoralchinesepatentmedicinesasadjuvanttherapyforcancerrelatedanemiaasystematicreviewandnetworkmetaanalysisofrandomizedcontrolledtrials AT yimingpan effectivenessandsafetyofsevenoralchinesepatentmedicinesasadjuvanttherapyforcancerrelatedanemiaasystematicreviewandnetworkmetaanalysisofrandomizedcontrolledtrials AT lihou effectivenessandsafetyofsevenoralchinesepatentmedicinesasadjuvanttherapyforcancerrelatedanemiaasystematicreviewandnetworkmetaanalysisofrandomizedcontrolledtrials |